A Search Service for Abbreviation / Long Form

■ Abbreviation / Long Form : EC / epirubicin and cyclophosphamide

[Related PubMed/MEDLINE]
Total Number of Papers: 72
[Entries Per Page]
 per page
Page Control
Page: of
Abbreviation:   EC  (>> Co-occurring Abbreviation)
Long Form:   epirubicin and cyclophosphamide
 Abbreviation Variation
 Long Form Variation
 Pair(Abbreviation/Long Form) Variation
No. Year Title Co-occurring Abbreviation
2019 Dose intensity in anthracycline-based chemotherapy for metastatic breast cancer: mature results of the randomised clinical trial ANZ 9311. ---
2019 Prophylactic administration of granulocyte colony-stimulating factor in epirubicin and cyclophosphamide chemotherapy for Japanese breast cancer patients: a retrospective study. FN, G-CSF
2019 Weekly carboplatin plus neoadjuvant anthracycline-taxane-based regimen in early triple-negative breast cancer: a prospective phase II trial by the Breast Cancer Task Force of the Belgian Society of Medical Oncology (BSMO). BSMO, CP, DD, G-CSF
2019 [Two Cases of Pneumocystis Pneumonia during Adjuvant Chemotherapy for Breast Cancer]. DTX, HIV, PCP, PSL
2018 Feasibility of dose-dense epirubicin and cyclophosphamide with subcutaneous pegfilgrastim 3.6mg support: a single-center prospective study in Japan. G-CSF, RDI
2018 Long-term safety and survival outcomes from the Scandinavian Breast Group 2004-1 randomized phase II trial of tailored dose-dense adjuvant chemotherapy for early breast cancer. ---
2017 Anti-Phosphohistone H3-Positive Mitoses Are Linked to Pathological Response in Neoadjuvantly Treated Breast Cancer. BC, HPF, NACT, pCR, PHH3, TN
2017 Epirubicin With Cyclophosphamide Followed by Docetaxel With Trastuzumab and Bevacizumab as Neoadjuvant Therapy for HER2-Positive Locally Advanced Breast Cancer or as Adjuvant Therapy for HER2-Positive Pathologic Stage III Breast Cancer: A Phase II Trial of the NSABP Foundation Research Group, FB-5. CEs, CI, LABC, OS, pCR, PS3BC, RFS
2017 Preoperative neoadjuvant chemotherapy using nanoparticle albumin-bound paclitaxel followed by epirubicin and cyclophosphamide for operable breast cancer: a multicenter phase II trial. HER2, nab-PTX, NAC, pCR
10  2017 [Analysis of the factors influencing adjuvant chemotherapy decisions for triple negative breast cancer]. MDT, TNBC, wP
11  2016 Cyclophosphamide and epirubicin-induced diabetes mellitus in breast cancer: A rare occurrence. ---
12  2016 Higher rate of severe toxicities in obese patients receiving dose-dense (dd) chemotherapy according to unadjusted body surface area: results of the prospectively randomized GAIN study. BSA, DD, DFS, OS
13  2016 [Safety and Tolerance of Dose-Dense Epirubicin and Cyclophosphamide (EC) with Pegfilgrastim for Japanese Patients with Early Breast Cancer]. RDI
14  2015 A randomized phase 2 study comparing EC or CMF versus nab-paclitaxel plus capecitabine as adjuvant chemotherapy for nonfrail elderly patients with moderate to high-risk early breast cancer (ICE II-GBG 52). CMF, HER2, IADL, nPX
15  2015 Epirubicin Plus Cyclophosphamide Followed by Docetaxel Versus Epirubicin Plus Docetaxel Followed by Capecitabine As Adjuvant Therapy for Node-Positive Early Breast Cancer: Results From the GEICAM/2003-10 Study. BC, OS
16  2015 Phase II Study of Neoadjuvant Anthracycline-Based Regimens Combined With Nanoparticle Albumin-Bound Paclitaxel and Trastuzumab for Human Epidermal Growth Factor Receptor 2-Positive Operable Breast Cancer. HER2, nab, pCR
17  2015 UNICANCER-PEGASE 07 study: a randomized phase III trial evaluating postoperative docetaxel-5FU regimen after neoadjuvant dose-intense chemotherapy for treatment of inflammatory breast cancer. CI, D-5FU, DFS, DI, HR, IBC, OS, pCR
18  2015 [A Case of Locally-Advanced Breast Cancer with Liver Metastasis, Treated with Mastectomy of the Primary Tumor after Chemotherapy]. CR, DOC, NG, PER, PR
19  2014 Final analysis of the prospective WSG-AGO EC-Doc versus FEC phase III trial in intermediate-risk (pN1) early breast cancer: efficacy and predictive value of Ki67 expression. BC, EFS, HR, LNs, OS
20  2014 [The case of a long-surviving patient with breast cancer and brain metastases treated using multidisciplinary therapy]. CT
21  2013 Feasibility and safety of dose-dense docetaxel after conventional epirubicin and cyclophosphamide as adjuvant treatment for early breast cancer patients. ---
22  2013 Neoadjuvant chemotherapy with paclitaxel and everolimus in breast cancer patients with non-responsive tumours to epirubicin/cyclophosphamide (EC) bevacizumab - results of the randomised GeparQuinto study (GBG 44). CI, mTOR
23  2013 [A case of facial nerve palsy induced by nab-paclitaxel]. ---
24  2013 [A case of triple-negative breast cancer achieved pCR by epirubicin and cyclophosphamide(EC)therapy followed by gemcitabine plus paclitaxel combination preoperative therapy]. PR, TNBC
25  2013 [A patient with thyroid cancer evaluated according to Response Evaluation Criteria in Solid Tumors during treatment for breast cancer recurrence in hepatic and cervical lymph nodes]. CR, CT, PD, PTX, RECIST
26  2013 [Incidence of dysgeusia associated with chemotherapy for cancer]. DTX, PTX
27  2013 [Indoleamine 2, 3-dioxygenase activity during neoadjuvant chemotherapy in patients with breast cancer]. HPLC, IDO, KYN, Trp, wPAC
28  2012 A multicenter phase III prospective randomized trial of high-dose epirubicin in combination with cyclophosphamide (EC) versus docetaxel followed by EC in node-positive breast cancer. GOIM (Gruppo Oncologico Italia Meridionale) 9902 study. DFS, GOIM, OS
29  2012 [A case of breast cancer treated with neoadjuvant chemotherapy and segmentectomy]. ER, HER2, MRI, PgR
30  2012 [Indoleamine 2, 3-dioxygenase activity during chemotherapy or trastuzumab therapy in patients with breast cancer]. HPLC, IDO, KYN, Trp, wPTX
31  2011 A randomised feasibility/phase II study (SBG 2004-1) with dose-dense/tailored epirubicin, cyclophoshamide (EC) followed by docetaxel (T) or fixed dosed dose-dense EC/T versus T, doxorubicin and C (TAC) in node-positive breast cancer. TAC
32  2011 Current strategy for triple-negative breast cancer: appropriate combination of surgery, radiation, and chemotherapy. BCT, DTX, pCR, TNBC
33  2011 Effect of adding gefitinib to neoadjuvant chemotherapy in estrogen receptor negative early breast cancer in a randomized phase II trial. AE, CR, OR, pCR, TNBC
34  2011 Integrating bevacizumab, everolimus, and lapatinib into current neoadjuvant chemotherapy regimen for primary breast cancer. Safety results of the GeparQuinto trial. HER
35  2011 Value of post-operative reassessment of estrogen receptor alpha expression following neoadjuvant chemotherapy with or without gefitinib for estrogen receptor negative breast cancer. ER
36  2011 [Efficacy and safety of aprepitant in patients with breast cancer]. ---
37  2011 [Responses to primary systemic therapy for breast cancer as assessed by hormone receptor and HER2 status]. DTX, ER, HR, pCR, PgR, PST, PTX
38  2010 Capecitabine in addition to anthracycline- and taxane-based neoadjuvant treatment in patients with primary breast cancer: phase III GeparQuattro study. HER2
39  2010 Cyclophosphamide, epirubicin, and Fluorouracil versus dose-dense epirubicin and cyclophosphamide followed by Paclitaxel versus Doxorubicin and cyclophosphamide followed by Paclitaxel in node-positive or high-risk node-negative breast cancer. CEF, RFS
40  2010 Epirubicin and cyclophosphamide versus epirubicin and docetaxel as first-line therapy for women with metastatic breast cancer: final results of a randomised phase III trial. HR, ORR, OS, PFS
41  2010 ERBB2 and TOP2A in breast cancer: a comprehensive analysis of gene amplification, RNA levels, and protein expression and their influence on prognosis and prediction. MFI
42  2010 Prediction of breast cancer sensitivity to neoadjuvant chemotherapy based on status of DNA damage repair proteins. DDR, DSBs
43  2010 Sequential administration of dose-dense epirubicin/cyclophosphamide followed by docetaxel/capecitabine for patients with HER2-negative and locally advanced or node-positive breast cancer. HFS, MBC
44  2010 [A case of giant advanced ulcerative breast cancer managed with epirubicin and cyclophosphamide followed by weekly paclitaxel]. ---
45  2009 A randomised pilot Phase II study of doxorubicin and cyclophosphamide (AC) or epirubicin and cyclophosphamide (EC) given 2 weekly with pegfilgrastim (accelerated) vs 3 weekly (standard) for women with early breast cancer. ---
46  2008 Epirubicin and cyclophosphamide followed by docetaxel as primary systemic chemotherapy in locally advanced breast cancer. CR, PST
47  2008 Prolonged dose-dense epirubicin and cyclophosphamide followed by paclitaxel in breast cancer is feasible. ---
48  2008 [Adjuvant epirubicin and cyclophosphamide followed by weekly paclitaxel for Japanese women with node-positive breast cancer: a multi-institutional feasibility study]. wPTX
49  2007 A randomised trial of goserelin versus control after adjuvant, risk-adapted chemotherapy in premenopausal patients with primary breast cancer - GABG-IV B-93. CI, CMF, HR, LN
50  2007 Low LATS2 mRNA level can predict favorable response to epirubicin plus cyclophosphamide, but not to docetaxel, in breast cancers. DOC
51  2006 Breast cancer in limited-resource countries: treatment and allocation of resources. CMF, FAC, LHRH
52  2006 Does granulocyte colony-stimulating factor worsen anemia in early breast cancer patients treated with epirubicin and cyclophosphamide? G-CSF, Hb
53  2006 Serum levels of IGF-1 and IGFBP-3 during adjuvant chemotherapy for primary breast cancer. FEC, IGF-1, IGFBP-3
54  2005 Impact of five prophylactic filgrastim schedules on hematologic toxicity in early breast cancer patients treated with epirubicin and cyclophosphamide. G-CSF
55  2005 Phase III trial of epirubicin plus paclitaxel compared with epirubicin plus cyclophosphamide as first-line chemotherapy for metastatic breast cancer: United Kingdom National Cancer Research Institute trial AB01. EP, MBC
56  2005 Predictive biological markers for response of invasive breast cancer to anthracycline/cyclophosphamide-based primary (radio-)chemotherapy. EGFR, ER, IHC, pCR, PgR
57  2005 Predictors of primary breast cancers responsiveness to preoperative epirubicin/cyclophosphamide-based chemotherapy: translation of microarray data into clinically useful predictive signatures. pCR, PLS-DA, PR, PST
58  2004 Anthracycline and trastuzumab in breast cancer treatment. LVEF
59  2004 Breast tumour growth inhibition in vitro through the combination of cyclophosphamide/metotrexate/5-fluorouracil, epirubicin/cyclophosphamide, epirubicin/paclitaxel, and epirubicin/docetaxel with the bisphosphonates ibandronate and zoledronic acid. ATP-CVA, CMF, EDoc, ET, HCM, IB, ZOL
60  2004 Cardiac safety of trastuzumab in combination with epirubicin and cyclophosphamide in women with metastatic breast cancer: results of a phase I trial. EC90, HER2, LVEF, MBC
61  2004 Effect of filgrastim on serum lactate dehydrogenase and alkaline phosphatase values in early breast cancer patients. AP, LDH
62  2004 Her-2/neu gene amplification and response to paclitaxel in patients with metastatic breast cancer. CI, ET, OR, RR
63  2004 Modulation of thymidine phosphorylase by neoadjuvant chemotherapy in primary breast cancer. 5-FU, AC, FAC, FEC, TP
64  2003 Addition of either lonidamine or granulocyte colony-stimulating factor does not improve survival in early breast cancer patients treated with high-dose epirubicin and cyclophosphamide. BC, DFS, G-CSF, LND, OS
65  2003 Adjuvant treatment of breast cancer patients with 1-3 positive lymph nodes: vinorelbine plus epirubicin; vinorelbine plus epirubicin sequential followed up by paclitaxel; epirubicin plus cyclophosphamide; epirubicin plus cyclophosphamide sequential followed up by paclitaxel. A phase II study. EC/T, EV, EV/T
66  2003 Risk of acute leukemia following epirubicin-based adjuvant chemotherapy: a report from the National Cancer Institute of Canada Clinical Trials Group. CEF, CI, CMF, sAL
67  2002 HER-2 amplification and topoisomerase IIalpha gene aberrations as predictive markers in node-positive breast cancer patients randomly treated either with an anthracycline-based therapy or with cyclophosphamide, methotrexate, and 5-fluorouracil. CIs, CMF, HRs, topo IIalpha
68  2001 Ongoing trials with trastuzumab in metastatic breast cancer. ---
69  1998 Correlation between granulocyte/macrophage-colony-forming units and CD34+ cells in apheresis products from patients treated with different chemotherapy regimens and granulocyte-colony-stimulating factor to mobilize peripheral blood progenitor cells. CFU-GM, CHOEP, DexaBEAM, EPI/IFOS, PBPC
70  1998 Dose intensification of epidoxorubicin and cyclophosphamide in metastatic breast cancer: a randomised study with two schedules of granulocyte-macrophage colony stimulating factor. CR, GM-CSF, i.v, PR, s.c
71  1997 Less efficacy with alternating regimen as adjuvant chemotherapy in stage II node-positive breast cancer: results at 8 years (Pronacam 85). CMF, DFS, FECMP
72  1996 Blood coagulation during adjuvant epirubicin/cyclophosphamide chemotherapy in patients with primary operable breast cancer. DVT, ELISA, IPG, PAI